Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.

Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Ortolani S

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA1 Jan 1993Cited by 36 (Europe PMC)

PMID8298199DOI10.1007/bf01623004PepBankPUB-08298199

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, calcitonin did not significantly increase spine bone mineral density relative to placebo.
In plain wordsIn postmenopausal women with osteoporosis, calcitonin did not significantly increase spine bone density compared with placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeSpine bone mineral density versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
In contrast, CT failed to significantly increase BMD of either the spine, femoral neck or trochanter, either relative to baseline or to PBO.(ABSTRACT TRUNCATED AT 250 WORDS)
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if daily oral ALN treatment could prevent or reverse bone loss in osteoporotic postmenopausal women, and to compare ALN to intranasal salmon calcitonin (CT), a 2-year, double-masked, randomized, placebo-controlled study was initiated at 9 clinical centers in Italy.
Summary · context
A planned 1-year interim analysis of this ongoing study was performed centrally in a manner that maintains the double-mask for all subjects receiving oral study drug.
Report a problemFND-0829819901
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, calcitonin did not significantly increase femoral neck bone mineral density relative to placebo.
In plain wordsIn postmenopausal women with osteoporosis, calcitonin did not significantly increase femoral neck bone density compared with placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeFemoral neck bone mineral density versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
In contrast, CT failed to significantly increase BMD of either the spine, femoral neck or trochanter, either relative to baseline or to PBO.(ABSTRACT TRUNCATED AT 250 WORDS)
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if daily oral ALN treatment could prevent or reverse bone loss in osteoporotic postmenopausal women, and to compare ALN to intranasal salmon calcitonin (CT), a 2-year, double-masked, randomized, placebo-controlled study was initiated at 9 clinical centers in Italy.
Summary · context
A planned 1-year interim analysis of this ongoing study was performed centrally in a manner that maintains the double-mask for all subjects receiving oral study drug.
Report a problemFND-0829819902
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, calcitonin did not significantly increase trochanter bone mineral density relative to placebo.
In plain wordsIn postmenopausal women with osteoporosis, calcitonin did not significantly increase trochanter bone density compared with placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeTrochanter bone mineral density versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
In contrast, CT failed to significantly increase BMD of either the spine, femoral neck or trochanter, either relative to baseline or to PBO.(ABSTRACT TRUNCATED AT 250 WORDS)
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if daily oral ALN treatment could prevent or reverse bone loss in osteoporotic postmenopausal women, and to compare ALN to intranasal salmon calcitonin (CT), a 2-year, double-masked, randomized, placebo-controlled study was initiated at 9 clinical centers in Italy.
Summary · context
A planned 1-year interim analysis of this ongoing study was performed centrally in a manner that maintains the double-mask for all subjects receiving oral study drug.
Report a problemFND-0829819903
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, intranasal calcitonin 100 IU daily did not significantly increase trochanter bone mineral density relative to baseline or to placebo in the planned 1-year interim analysis.
In plain wordsIn postmenopausal women with osteoporosis, calcitonin did not significantly increase trochanter bone density compared with baseline or placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeTrochanter bone mineral density change
Study
n: not reported in source
Comparator
Placebo and baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
In contrast, CT failed to significantly increase BMD of either the spine, femoral neck or trochanter, either relative to baseline or to PBO.(ABSTRACT TRUNCATED AT 250 WORDS)
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if daily oral ALN treatment could prevent or reverse bone loss in osteoporotic postmenopausal women, and to compare ALN to intranasal salmon calcitonin (CT), a 2-year, double-masked, randomized, placebo-controlled study was initiated at 9 clinical centers in Italy.
Summary · context
A planned 1-year interim analysis of this ongoing study was performed centrally in a manner that maintains the double-mask for all subjects receiving oral study drug.
Report a problemFND-0829819906
05HumanNon-randomized trialEfficacy outcome
In postmenopausal women with osteoporosis, calcitonin did not significantly increase spine bone mineral density relative to baseline.
In plain wordsIn postmenopausal women with osteoporosis, spine bone density did not significantly increase from baseline with calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeSpine bone mineral density change
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
In contrast, CT failed to significantly increase BMD of either the spine, femoral neck or trochanter, either relative to baseline or to PBO.(ABSTRACT TRUNCATED AT 250 WORDS)
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if daily oral ALN treatment could prevent or reverse bone loss in osteoporotic postmenopausal women, and to compare ALN to intranasal salmon calcitonin (CT), a 2-year, double-masked, randomized, placebo-controlled study was initiated at 9 clinical centers in Italy.
Summary · context
A planned 1-year interim analysis of this ongoing study was performed centrally in a manner that maintains the double-mask for all subjects receiving oral study drug.
Report a problemFND-0829819904
06HumanNon-randomized trialEfficacy outcome
In postmenopausal women with osteoporosis, calcitonin did not significantly increase femoral neck bone mineral density relative to baseline.
In plain wordsIn postmenopausal women with osteoporosis, femoral neck bone density did not significantly increase from baseline with calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeFemoral neck bone mineral density change
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
In contrast, CT failed to significantly increase BMD of either the spine, femoral neck or trochanter, either relative to baseline or to PBO.(ABSTRACT TRUNCATED AT 250 WORDS)
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if daily oral ALN treatment could prevent or reverse bone loss in osteoporotic postmenopausal women, and to compare ALN to intranasal salmon calcitonin (CT), a 2-year, double-masked, randomized, placebo-controlled study was initiated at 9 clinical centers in Italy.
Summary · context
A planned 1-year interim analysis of this ongoing study was performed centrally in a manner that maintains the double-mask for all subjects receiving oral study drug.
Report a problemFND-0829819905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.